Aquestive Therapeutics Q2 2023 Earnings Report

Aquestive Therapeutics EPS Results

• Actual EPS: -$0.10
• Consensus EPS: -$0.11
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

Aquestive Therapeutics Revenue Results

• Actual Revenue: $13.24 million
• Expected Revenue: $10.76 million
• Beat/Miss: Beat by +$2.48 million
• YoY Revenue Growth: N/A

Aquestive Therapeutics Announcement Details

• Quarter: Q2 2023
• Date: 8/7/2023
• Time: N/A

Aquestive Therapeutics (NASDAQ:AQST) operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.